Felix Hilpert

Felix Hilpert

UNVERIFIED PROFILE

Are you Felix Hilpert?   Register this Author

Register author
Felix Hilpert

Felix Hilpert

Publications by authors named "Felix Hilpert"

Are you Felix Hilpert?   Register this Author

82Publications

2851Reads

48Profile Views

TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).

Int J Gynecol Cancer 2019 10 15;29(8):1327-1331. Epub 2019 Aug 15.

AGO Study Group and Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University Munich, Munich, Bayern, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2019-000682DOI Listing
October 2019

Early treatment modifications improve chemotherapy adherence in ovarian cancer patients ≥70 years.

Gynecol Oncol 2019 06 21;153(3):616-624. Epub 2019 Mar 21.

Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Kiel, Germany; Onkologisches Therapiezentrum, Krankenhaus Jerusalem, Hamburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.02.015DOI Listing
June 2019

Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study.

Gynecol Oncol 2019 05 11;153(2):286-291. Epub 2019 Feb 11.

Department of Gynaecology and Gynaecologic Oncology, University Medical Center Hamburg-Eppendorf, Germany; Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.02.007DOI Listing
May 2019

A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms.

N Engl J Med 2019 02;380(9):822-832

From the Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen (P. Harter, A. du Bois), Department of Gynecology, Charité-Universitätsmedizin Berlin, Berlin (J.S.), the Coordinating Center for Clinical Trials, Philipps University Marburg (A.R., C.S.-B.), and the Department of Gynecology and Obstetrics, University Hospital Giessen and Marburg (U.W.), Marburg, the Department of Gynecology and Obstetrics, Kaiserswerther Diakonie (B.L.), and the Department of Obstetrics and Gynecology, Heinrich-Heine-University Düsseldorf (W.M.), Düsseldorf, the Department of Gynecology and Obstetrics, University Medicine Greifswald, Greifswald (A.M.), the Department of Gynecology, University Medical Center Hamburg-Eppendorf (S.M.), and the Department of Gynecology and Obstetrics, Albertinen Krankenhaus (I.L.), Hamburg, University Women's Hospital, Department of Gynecology and Reproductive Medicine and Center for Gynecologic Oncology, Jena University Hospital, Jena (I.B.R.), the Department of Obstetrics and Gynecology, University Munich rechts der Isar (B.S.), and the Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-Universität München (A. Burges), Munich, West German Cancer Center, Department of Gynecology and Obstetrics, University of Duisburg-Essen, Duisburg (R.K.), the Department of Gynecology and Obstetrics, University Hospital Kiel, Kiel (F.H.), University Medical Center Freiburg, Freiburg (A.H.), University Medical Center Mainz, Department of Gynecology and Obstetrics, Mainz (A.H.), and the Department of Gynecology and Obstetrics, Hannover Medical School, Hannover (P. Hillemanns) - all in Germany; the Gynecologic Oncology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale Tumori (D.L., F.R.), and the Department of Gynecologic Oncology, European Institute of Oncology, University of Milan (G.A.), Milan, the Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome (G.S.), Gynecologic Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori di Napoli, IRCCS Fondazione G. Pascale, Naples (S.G.), and the Cancer Reference Center, Centro di Riferimento Oncologico, Aviano (G.G.) - all in Italy; the Department of Gynecological Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium (I.V.); the Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria (C.M.); the Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea (J.-W.K.); and the Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic (D.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1808424DOI Listing
February 2019

Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) - Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities.

Geburtshilfe Frauenheilkd 2018 Nov 26;78(11):1089-1109. Epub 2018 Nov 26.

Klinik für Gynäkologie und Geburtshilfe, Universitätsmedizin Göttingen, Göttingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-0715-2964DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261739PMC
November 2018

Patient-reported outcomes in ovarian cancer: are they key factors for decision making?

Expert Rev Anticancer Ther 2018 10;18(sup1):3-7

b Klinik für Gynäkologie & Gynäkologische Onkologie , Kliniken Essen-Mitte , Essen , Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2018.1516146DOI Listing
October 2018

Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) - Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer.

Geburtshilfe Frauenheilkd 2018 Oct 19;78(10):949-971. Epub 2018 Oct 19.

Klinik für Gynäkologie und Geburtshilfe, Universitätsmedizin Göttingen, Göttingen, Germany.

View Article

Download full-text PDF

Source
http://www.thieme-connect.de/DOI/DOI?10.1055/a-0713-1218
Publisher Site
http://dx.doi.org/10.1055/a-0713-1218DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195426PMC
October 2018

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Lancet Oncol 2018 09 9;19(9):1247-1258. Epub 2018 Aug 9.

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany; Berlin Institute of Health, Department of Gynecology with Center for Oncological Surgery, Berlin, Germany.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045183037
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(18)30372-3DOI Listing
September 2018

Comparative analysis of surface coating properties of five hydrophobins from Aspergillus nidulans and Trichoderma reseei.

Sci Rep 2018 08 13;8(1):12033. Epub 2018 Aug 13.

Department of Microbiology, Institute for Applied Biosciences, Karlsruhe Institute of Technology (KIT), Karlsruhe, Germany.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41598-018-29749-0
Publisher Site
http://dx.doi.org/10.1038/s41598-018-29749-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089913PMC
August 2018

Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.

J Clin Oncol 2016 12 23;34(36):4345-4353. Epub 2016 Oct 23.

Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.1891DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562430PMC
December 2016

Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).

Gynecol Oncol 2016 Mar 28;140(3):450-6. Epub 2015 Dec 28.

Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik für Gynäkologie und Geburtshilfe, Arnold-Heller-Str. 3, Haus 24, 24105 Kiel, Germany,. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2015.12.025DOI Listing
March 2016

Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.

Mol Cancer Ther 2015 Jun 7;14(6):1495-503. Epub 2015 Apr 7.

Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. Department of Pathology, The University of Melbourne, Parkville, Victoria, Australia. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-15-0039DOI Listing
June 2015

Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study.

J Natl Cancer Inst 2015 Mar 24;107(3). Epub 2015 Jan 24.

Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (SM, LFG, LW); Department of Obstetrics and Gynecology, University Hospital Munich Maistrasse, Munich, Germany (JJ); Department of Obstetrics and Gynecology, University Medical Center Kiel, Kiel, Germany (FH); KKS Philipps University Marburg, Marburg, Germany (PN); Department of Gynecology and Gynecologic Oncology Kliniken Essen-Mitte, Essen, Germany (PH, AdB); Department of Obstetrics and Gynecology, University of Ulm Medical Center, Ulm, Germany (NdG); Department of Gynecology and Gynecologic Oncology, University Hospital Freiburg, Freiburg, Germany (AHas); Department of Gynecology, Charité University Medicine Berlin Campus Virchow, Berlin, Germany (JS); Department of Obstetrics and Gynecology, University Hospital Magdeburg, Magdeburg, Germany (AHab); Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany (PH); Department of Obstetrics and Gynecology, Grosshadern University Hospital, Munich, Germany (SF); Department of Gynecology, University Hospital Halle, Halle, Germany (HGS); Department of Gynecology and Gynecologic Oncology, Philipps University Marburg, Marburg, Germany (KB); Department of Gynecology, University Hospital Erlangen, Erlangen, Germany (FT); Department of Obstetrics and Gynecology, University Hospital Greifswald, Greifswald, Germany (AM); Department of Obstetrics and Gynecology, Evangelical Hospital Duesseldorf, Duesseldorf, Germany (WM).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju426DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356703PMC
March 2015

Gynecologic Cancer InterGroup (GCIG) consensus review for squamous cell carcinoma of the ovary.

Int J Gynecol Cancer 2014 Nov;24(9 Suppl 3):S26-9

*Beatson West of Scotland Cancer Centre, Glasgow, UK (SGCTG); †Medical Oncology Department, MD Anderson Cancer Centre, Madrid, Spain (GEICO); ‡Southern General Hospital, Glasgow, UK (SGCTG); §Gynecologic Oncology Unit, Fondazione IRCCS National Cancer institute of Milan (MITO), Milan, Italy; ‖Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden (NSGO); ¶Division of Gynecologic Oncology, NorthShore University Health System, University of Chicago Pritzker School of Medicine, Evanston, IL (GOG); #The Canberra Hospital, Canberra, Australia (ANZGOG); **University Hospital of Schleswig-Holstein Campus, Kiel, Germany (AGO); ††Department of Obstectrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea (KGOG); ‡‡Medical Oncology, Cochin-Hôtel Dieu, Paris Descartes University, Paris, France (GINECO); and §§UCL Cancer Institute, London, UK (NCRI/MRC).

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/ijgc/2014/11003/Gynecologic_Can
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/IGC.0000000000000209DOI Listing
November 2014

Reply to F. Tomao et al.

J Clin Oncol 2014 Nov 2;32(31):3580. Epub 2014 Sep 2.

Instituto Valenciano de Oncologia, Valencia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.7379DOI Listing
November 2014

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors).

Int J Gynecol Cancer 2014 Nov;24(9 Suppl 3):S5-8

*Kliniken-Essen-Mitte, AGO, Essen, Germany; †MD Andersen Cancer Center, GOG, Houston, TX; ‡Gustave Roussy, GINECO, Villejuif Cedex, France; §Université René Descartes, GINECO, Paris, France; ∥UCL Cancer Institute, MRC NCRI, London, United Kingdom; ¶CHUM-Notre-Dame Hospital, NCIC-CTG, Montreal, Quebec, Canada; #Fondazione IRCCS Istituto Nazionale dei Tumori, MITO, Milan, Italy; **ANZGOG, Parkville, Victoria, Australia; ††University and University Hospital of Tampere, NSGO, Tampere, Finland; ‡‡Seoul National University, KGOG, Seoul, South Korea; §§University Medical Center Hamburg-Eppendorf, AGO, Hamburg, Germany; ∥∥University Hospital Kiel, AGO, Kiel, Germany; ¶¶UKGM, Marburg, AGO, Marburg, Germany; and ##Gynecologic Oncology Center, Kiel, AGO, Kiel, Germany.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/ijgc/2014/11003/Gynecologic_Can
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/IGC.0000000000000282DOI Listing
November 2014

Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract.

Int J Gynecol Cancer 2014 Nov;24(9 Suppl 3):S78-82

From the *Australia and New Zealand Gynecological Oncology Group (ANZGOG); †Sunnybrook Hospital, Toronto, Canada, (GOG); ‡Beatson West of Scotland Cancer Centre, Glasgow, Scotland, (SGCTG); §University Hospital of Schleswig-Holstein Campus Kiel, Germany, (AGO); ∥Norwegian Radium Hospital, Oslo, Norway, (NSGO); ¶School of Medicine, Dongsan Hospital, Keimyung University, Korea, (KGOG); #Centre Leon Berard, Lyon, France, (GINECO); **Department of Radiation Oncology, Stritch School of Medicine, Loyola University, Chicago, IL, (RTOG); ††University Medical Center, Utrecht Cancer Center, Utrecht, the Netherlands, (DGOG); and the ‡‡Department of Obstetrics Gynaecology and Neonatology, The University of Sydney, Sydney, New South Wales, Australia, (ANZGOG).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000000239DOI Listing
November 2014

Frequent translocations of 11q13.2 and 19p13.2 in ovarian cancer.

Genes Chromosomes Cancer 2014 Jun 24;53(6):447-53. Epub 2014 Feb 24.

Department of Gynecology, Zhejiang University School of Medicine, The 2nd Affiliated Hospital, Hangzhou, Zhejiang, China; Clinic of Gynecology and Obstetrics, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.22152DOI Listing
June 2014

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.

J Clin Oncol 2014 May 17;32(13):1302-8. Epub 2014 Mar 17.

Eric Pujade-Lauraine, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, Paris; Béatrice Weber, GINECO and Centre Alexis Vautrin, Vandoeuvre-les-Nancy; Philippe Follana, GINECO and Centre Antoine-Lacassagne, Nice; Isabelle Ray-Coquard, GINECO and Centre Léon Bérard, Lyon, France; Felix Hilpert, Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and Klinik für Gynäkologie und Geburtshilfe, Kiel; Alexander Reuss, AGO and Coordinating Center for Clinical Trials, Marburg; Pauline Wimberger, AGO and University of Duisburg-Essen, Essen, Germany; Andres Poveda, Grupo Español de Investigación en Cáncer de Ovario (GEICO) and Instituto Valenciano de Oncologia, Valencia; Ana Oaknin, GEICO and Vall d'Hebron University Hospital, Barcelona, Spain; Gunnar Kristensen, Nordic Society of Gynaecological Oncology (NSGO) and Norwegian Radium Hospital, Oslo, Norway; Roberto Sorio, Multicenter Italian Trials in Ovarian Cancer and Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy; Ignace Vergote, Belgian Gynaecological Oncology Group and University Hospital Leuven, Leuven, Belgium; Petronella Witteveen, Dutch Gynecological Oncology Group and University Medical Center Utrecht, Utrecht, the Netherlands; Aristotelis Bamias, Hellenic Cooperative Oncology Group and University of Athens, Athens, Greece; Deolinda Pereira, GINECO and Instituto Português de Oncologia do Porto, Porto, Portugal; Mansoor Raza Mirza, NSGO and Rigshospitalet, Copenhagen, Denmark; and David Bollag, F. Hoffmann-La Roche, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.51.4489DOI Listing
May 2014

Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.

J Clin Oncol 2014 May 31;32(13):1309-16. Epub 2014 Mar 31.

Martin R. Stockler, Madeleine T. King, Chee Khoon Lee, The University of Sydney; Michael Friedlander, Prince of Wales Clinical School, University of New South Wales, Sydney, Australia; Felix Hilpert, Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and Klinik für Gynäkologie und Geburtshilfe, Kiel; Nikolaus de Gregorio, AGO and University of Ulm Medical Center, Ulm, Germany; Lari Wenzel, University of California Irvine, Irvine, CA; Florence Joly, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Centre François Baclesse, Caen; Eric Pujade-Lauraine, GINECO and Centre Hospitalier Universitaire Hotel Dieu, Paris, France; José Angel Arranz, Grupo Español de Investigación en Cáncer de Ovario and Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mansoor Raza Mirza, Nordic Society of Gynaecological Oncology and Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Roberto Sorio, Multicenter Italian Trials in Ovarian Cancer and Centro di Riferimento Oncologico-Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy; and Ulrich Freudensprung, Vesna Sneller, Gill Hales, F. Hoffmann-La Roche, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2014/03/28/JCO.2013.51
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.51.4240
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.51.4240DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876313PMC
May 2014

Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5).

Int J Gynecol Cancer 2014 Feb;24(2):260-5

*Georg-August-Universität Göttingen, Frauenklinik, Göttingen, Germany; †University Hospital "Dr. Georgy Stranski," Pleven, Bulgaria; ‡Kliniken Essen-Mitte, Evang. Huyssens-Stiftung/Knappschaft Krankenhaus, Klinik für Gynäkologische Onkologie; and §Universitätsklinikum Duisburg-Essen, Universitätsfrauenklinik, Essen; ∥St. Vincentius Kliniken, Klinik für Gynäkologie u. Geburtshilfe, Karlsruhe; ¶Klinikum der J. W. Goethe-Universität, Klinik für Frauenheilkunde u. Geburtshilfe, Frankfurt; #Universitätsklinikum Schleswig-Holstein, Klinik für Gynäkologie u. Geburtshilfe, Kiel; **Universität Erlangen-Nürnberg, Klinik für Frauenheilkunde, Erlangen; ††Klinikum Lüneburg, Frauenklinik, Lüneburg; ‡‡Æterna Zentaris GmbH, Frankfurt; and §§Charité Campus Virchow-Klinikum, Klinik für Frauenheilkunde und Geburtshilfe, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000000044DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921259PMC
February 2014

Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13).

Invest New Drugs 2013 Dec 5;31(6):1499-504. Epub 2013 Sep 5.

Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Henricistr. 92, 45136, Essen, Germany,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-013-0011-3DOI Listing
December 2013

Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review.

Histopathology 2013 Nov 2;63(5):704-12. Epub 2013 Sep 2.

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; Department of Gynecology and Obstetrics, Tuebingen University, Tuebingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.12219DOI Listing
November 2013

Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a sequential application at the human ovarian cancer cell line SKOV3.

Arch Gynecol Obstet 2013 Jul 7;288(1):173-82. Epub 2013 Feb 7.

Department of Gynecology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, People's Republic of China.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00404-013-2719-x
Publisher Site
http://dx.doi.org/10.1007/s00404-013-2719-xDOI Listing
July 2013

Breakpoint characterization of the der(19)t(11;19)(q13;p13) in the ovarian cancer cell line SKOV-3.

Genes Chromosomes Cancer 2013 May 30;52(5):512-22. Epub 2013 Jan 30.

Department of Obstetrics and Gynaecology, University Medical Center Schleswig-Holstein, Christian-Albrechts University, Kiel, Germany.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/gcc.22048
Publisher Site
http://dx.doi.org/10.1002/gcc.22048DOI Listing
May 2013

Evaluation of two different vacuum-assisted breast biopsy systems: Mammotome(R) system 11G/8G vs. ATEC(R) system 12G/9G.

Acta Radiol 2013 Mar 14;54(2):137-43. Epub 2013 Jan 14.

Bereich Mammadiagnostik und Intervention, Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1258/ar.2012.120420DOI Listing
March 2013

Treatment of elderly ovarian cancer patients in the context of controlled clinical trials: a joint analysis of the AGO Germany experience.

Onkologie 2012 24;35(3):76-81. Epub 2012 Feb 24.

Klinik für Gynäkologie und Geburtshilfe, UKSH Campus Kiel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000336829DOI Listing
September 2012

Diagnosis and management of an unilateral giant fibroadenoma of the breast in pregnancy.

Arch Gynecol Obstet 2012 Jan 25;285(1):235-7. Epub 2011 May 25.

Klinik für Gynäkologie und Geburtshilfe, UK-SH, Campus Kiel, Arnold-Heller-Straße 3 (Haus 24), 24105, Kiel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00404-011-1923-9DOI Listing
January 2012

Congenital retroperitoneal vascular anomalies: impact on pelvic surgery.

Arch Gynecol Obstet 2011 Nov 24;284(5):1169-73. Epub 2010 Dec 24.

Department of Obstetrics and Gynaecology, Kiel University Hospital, Arnold-Heller-Strasse 3, Building 24, 24105 Kiel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00404-010-1803-8DOI Listing
November 2011

Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials.

Support Care Cancer 2011 Sep 6;19(9):1421-7. Epub 2010 Aug 6.

Department of Obstetrics and Gynecology, Medical University Graz, Auenbruggerplatz 14, 8036, Graz, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-010-0969-8DOI Listing
September 2011

Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles.

Oncology 2011 16;80(1-2):12-20. Epub 2011 May 16.

Department of Gynecology, University Medical Center Aachen, RWTH, Aachen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000327746DOI Listing
September 2011

Surgery for recurrent ovarian cancer.

Womens Health (Lond) 2011 Sep;7(5):529-35

Department of Gynecology & Gynecological Oncology, Kliniken Essen-Mitte, Huyssen-Stiftung/Knappschaft GmbH, Essen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/whe.11.52DOI Listing
September 2011

[Use in special patient groups: beta-sympathomimetics in children and pregnant women].

Pharm Unserer Zeit 2011 Sep;40(5):417-21

UKSH-Campus Kiel, Klinik für Allgemeine Pädiatrie, Arnold-Heller-Straße 3, 24105 Kiel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pauz.201100437DOI Listing
September 2011

Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.

Expert Rev Anticancer Ther 2010 Jan;10(1):81-8

Department of Gynecology and Gynecologic Oncology, HSK, Dr Horst Schmidt Klinik, Ludwig-Erhard-Strasse 100, D-65199 Wiesbaden, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.09.165DOI Listing
January 2010

Prognostic factors for complete debulking in first- and second-line ovarian cancer.

Int J Gynecol Cancer 2009 Dec;19 Suppl 2:S14-7

Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik, Ludwig-Erhard Strasse 100,Wiesbaden, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/IGC.0b013e3181bffb3fDOI Listing
December 2009

[Evaluating treatment from the point of view of the patient -PROs (patient-reported outcomes)].

Onkologie 2009 10;32 Suppl 1:18-20. Epub 2009 Jun 10.

mamazone Südwest, Ladenburg, Deutschland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000215717DOI Listing
September 2009

Role of cytoreductive surgery in recurrent ovarian cancer.

Expert Rev Anticancer Ther 2009 Jul;9(7):917-22

Department of Gynecology and Gynecologic Oncology, HSK, Dr Horst Schmidt Klinik, Ludwig-Erhard-Str. 100, D-65199 Wiesbaden, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.09.49DOI Listing
July 2009

Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects.

J Cancer Res Clin Oncol 2008 Dec 9;134(12):1397-405. Epub 2008 May 9.

Department of Obstetrics and Gynecology, Campus Kiel, University of Kiel, Michaelisstrasse 16, 24105 Kiel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-008-0408-0DOI Listing
December 2008

Anti-idiotypic antibody abagovomab in advanced ovarian cancer.

Future Oncol 2008 Dec;4(6):769-73

Department of Gynecology and Obstetrics, University Clinic Schleswig-Holstein, Campus Kiel, Michaelisstrasse 16, 24105 Kiel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/14796694.4.6.769DOI Listing
December 2008

Aromatase inhibitors: a safety comparison.

Expert Opin Drug Saf 2007 Mar;6(2):165-74

University of Kiel, Gynaecology and Obstetrics Clinic, Kiel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14740338.6.2.165DOI Listing
March 2007

Optimizing the use of aromatase inhibitors in adjuvant therapy for postmenopausal patients with hormone-responsive early breast cancer: current and future prospects.

J Cancer Res Clin Oncol 2006 Jun 1;132(6):343-55. Epub 2006 Feb 1.

Clinic for Gynecology and Obstetrics, University of Kiel, 24105 Kiel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-006-0081-0DOI Listing
June 2006

The use of aromatase inhibitors in adjuvant therapy for early breast cancer.

Cancer Chemother Pharmacol 2005 Nov;56 Suppl 1:32-8

Klinik fur Gynakologie und Gerburtshilfe, University of Kiel, 24105, Kiel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-005-0101-9DOI Listing
November 2005

Electrofusion generates diverse DC-tumour cell hybrids for cancer immunotherapy.

Anticancer Res 2004 Mar-Apr;24(2B):929-34

Department of Otorhinolaryngology, Head and Neck Surgery, University of Kiel, Germany.

View Article

Download full-text PDF

Source
July 2004

A dendritic cell based hybrid cell vaccine generated by electrofusion for immunotherapy strategies in HNSCC.

Auris Nasus Larynx 2004 Jun;31(2):149-53

Department of Otorhinolaryngology, Head and Neck Surgery, University of Kiel, Arnold-Heller-Strasse 14, D-24105 Kiel, Germany.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S038581460400005
Publisher Site
http://dx.doi.org/10.1016/j.anl.2004.01.007DOI Listing
June 2004

Docetaxel-induced nail changes--a neurogenic mechanism: a case report.

J Neurooncol 2002 Jun;58(2):167-74

Klinik für Neurologie, Universitätsklinikum der Christian-Albrechts-Universität zu Kiel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1023/a:1016002329546DOI Listing
June 2002